These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24412634)

  • 1. Pathological fracture and pyogenic osteomyelitis in a patient with type 2 Gaucher disease.
    Hayashi A; Kawakita R; Kumada T; Nozaki F; Hiejima I; Miyajima T; Kusunoki T; Fujii T
    Brain Dev; 2014 Oct; 36(9):830-3. PubMed ID: 24412634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J; Szücs FZ; Benkö K; Maródi L
    Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fanconi syndrome caused by valproic acid.
    Endo A; Fujita Y; Fuchigami T; Takahashi S; Mugishima H
    Pediatr Neurol; 2010 Apr; 42(4):287-90. PubMed ID: 20304335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fanconi syndrome caused by sodium valproate: report of three severely disabled children.
    Yoshikawa H; Watanabe T; Abe T
    Eur J Paediatr Neurol; 2002; 6(3):165-7. PubMed ID: 12363104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S; Roberts A; Patterson MA; Amato D
    Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of women with Gaucher disease in the reproductive age.
    Rosenbaum H
    Thromb Res; 2015 Feb; 135 Suppl 1():S49-51. PubMed ID: 25903536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesenteric and Mediastinal Lymphadenopathy in Egyptian Children With Gaucher Disease Types 1 and 3 Treated With Enzyme Replacement Therapy.
    Abdelwahab M; SeifEldien HM
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):e316-22. PubMed ID: 25521082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fever of unknown origin as the initial manifestation of valproate-induced Fanconi syndrome.
    Nozaki F; Kumada T; Kusunoki T; Fujii T; Murayama K; Ohtake A
    Pediatr Neurol; 2014 Dec; 51(6):846-9. PubMed ID: 25439492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
    J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
    Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skeletal complications of type I Gaucher disease: the magnetic resonance features.
    Cremin BJ; Davey H; Goldblatt J
    Clin Radiol; 1990 Apr; 41(4):244-7. PubMed ID: 2340694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune haemolytic anaemia and renal Fanconi syndrome caused by valproate therapy.
    Watanabe T; Nakayasu K; Nagayama Y
    Eur J Pediatr; 2005 Mar; 164(3):186-7. PubMed ID: 15717181
    [No Abstract]   [Full Text] [Related]  

  • 13. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
    Potnis KC; Flueckinger LB; Ha CI; Upadia J; Frush DP; Kishnani PS
    Mol Genet Metab; 2019 Feb; 126(2):157-161. PubMed ID: 30448006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproate-induced proximal renal tubular dysfunction: clinically relevant in the severely disabled epileptic population.
    Jaffe SL; Sanford M
    Epilepsia; 2005 Apr; 46(4):599-600. PubMed ID: 15816962
    [No Abstract]   [Full Text] [Related]  

  • 15. Fractures and Fanconi syndrome due to prolonged sodium valproate use.
    Dhillon N; Högler W
    Neuropediatrics; 2011 Jun; 42(3):119-21. PubMed ID: 21717384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
    Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
    Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
    Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
    Boomsma JM; van Dussen L; Wiersma MG; Groener JE; Aerts JM; Maas M; Hollak CE
    Blood Cells Mol Dis; 2010 Mar; 44(3):181-7. PubMed ID: 20074983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kidney Biopsy Findings in a Patient With Valproic Acid-Associated Fanconi Syndrome.
    Singer P; Sethna CB; Castellanos-Reyes L; Yaskiv O; Bijol V
    Pediatr Dev Pathol; 2019; 22(4):370-374. PubMed ID: 30565480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM; Barnett NL; Kolodny EH
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.